Literature DB >> 6814243

Chlorpromazine-induced lupus anticoagulant and associated immunologic abnormalities.

R T Canoso, H S Sise.   

Abstract

Chronic administration of chlorpromazine is associated with the development of a lupus-like circulating anticoagulant and a variety of immunological abnormalities. The prevalence of these findings was studied in 123 psychiatric patients. The anticoagulant was present in 11 of 30 patients receiving chlorpromazine (CPZ), in none of 17 patients who had been off phenothiazine therapy for over a year and in none of 53 controls. It was also seen in 5 of 13 patients who had been switched from CPZ to another phenothiazine even after several years being off CPZ. The anticoagulant was characterized by prolongation of the partial thromboplastin time, thromboplastin dilution test, and Russell's viper venom time. Washed frozen platelets partially corrected the abnormality induced by the anticoagulant. In all but one case the anticoagulant was associated with positive antinuclear antibody test and/or increased serum IgM. Six of 16 patients also had decreased complement levels, and two had a positive direct Coombs' test. None of these patients manifested bleeding, hemolysis, splenomegaly, or other clinical features of systemic lupus erythematosus.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6814243     DOI: 10.1002/ajh.2830130204

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  20 in total

Review 1.  Drug-induced lupus anticoagulants and antiphospholipid antibodies.

Authors:  Jeffrey S Dlott; Robert A S Roubey
Journal:  Curr Rheumatol Rep       Date:  2012-02       Impact factor: 4.592

Review 2.  Drug-induced lupus erythematosus: incidence, management and prevention.

Authors:  Christopher Chang; M Eric Gershwin
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

3.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

4.  The effects of selected drugs, including chlorpromazine and non-steroidal anti-inflammatory agents, on polyclonal IgG synthesis and interleukin 1 production by human peripheral blood mononuclear cells in vitro.

Authors:  F Martinez; J W Coleman
Journal:  Clin Exp Immunol       Date:  1989-05       Impact factor: 4.330

Review 5.  Antiphospholipid antibodies and the antiphospholipid syndrome.

Authors:  E N Harris; S S Pierangeli
Journal:  Springer Semin Immunopathol       Date:  1994

Review 6.  The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

Authors:  E N Harris
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

7.  Spinal subdural haematoma in a parturient after attempted epidural anaesthesia.

Authors:  T T Lao; S H Halpern; D MacDonald; C Huh
Journal:  Can J Anaesth       Date:  1993-04       Impact factor: 5.063

8.  Incidence of arteriovenous thrombosis and the role of anticardiolipin antibodies in hemodialysis patients.

Authors:  Roozbeh Jamshid; Serati Ali Reza; Ghaderi Abbas; Afshariani Raha
Journal:  Int Urol Nephrol       Date:  2003       Impact factor: 2.370

9.  Different clinical presentations of a lupus anticoagulant in the same family.

Authors:  R M Jolidon; H Knecht; L Humair; A de Torrente
Journal:  Klin Wochenschr       Date:  1991-05-24

10.  Anticardiolipin antibodies: isotype distribution and phospholipid specificity.

Authors:  A E Gharavi; E N Harris; R A Asherson; G R Hughes
Journal:  Ann Rheum Dis       Date:  1987-01       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.